Navigation Links
Cystic Fibrosis Foundation funds Marshall research

HUNTINGTON, W.Va. The Cystic Fibrosis Foundation has awarded a Marshall University scientist a two-year, $194,400 grant.

The grant to Dr. Hongwei Yu, professor in the Department of Biochemistry and Microbiology at the university's Joan C. Edwards School of Medicine, will help further his lab's work to explore the factors that control the overproduction of mucus in the lungs of cystic fibrosis (CF) patients.

According to Yu, chronic bronchial pneumonia caused by the bacterium Pseudomonas aeruginosa is a life-threatening condition for patients with CF.

"During these infections in CF patients, the bacterium is capable of producing copious amounts of alginatea thick, sugar-like polymer that plugs the airways, making breathing difficult," he said. "The alginate also helps form a thick, slimy 'biofilm' around the colonies of bacteria, protecting them from the body's immune defense mechanisms and making antibiotic treatment less effective."

Yu said the long-range goal of his research is to better understand the mechanisms of how this bacterium regulates production of the alginate biofilms in order to develop a more effective treatment option to inhibit or suppress the formation of alginate biofilms in the lungs of CF patients.

"For this project, we will be accessing the relevance of two newly identified proteins that act as alginate regulators. Once the mechanisms controlling alginate production are fully understood, it may be possible to improve treatment of these bacterial infections in CF patients by modulating or suppressing that production," he added.

Dr. John Maher, Marshall's vice president for research, congratulated Yu and praised him and his team for obtaining the grant.

"Dr. Yu's work is an excellent example of the vital research here at Marshall University that can affect the health and welfare of people everywhere. Research in his lab has the potential to have a real impact on the quality of life for people with cystic fibrosis," said Maher.

Maher also noted that Yu's research has had a regional economic development impact, saying his work has led to a patent and the development of Progenesis Technologies LLC, a West Virginia-based biotech research and development company. A second patent is pending.


Contact: Ginny Painter
Marshall University Research Corporation

Related biology news :

1. Pig model of cystic fibrosis improves understanding of disease
2. Breakthrough on cystic fibrosis 1 step closer as new research alliance formed
3. Women with polycystic ovary syndrome may be more vulnerable to BPA
4. Common diabetes drug may halt growth of cysts in polycystic kidney disease
5. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
6. Drug may treat cystic fibrosis, other diseases caused by nonsense mutations, UAB researcher says
7. Research project yields better understanding of the defective protein that causes cystic fibrosis
8. Cystic fibrosis testing -- next steps
9. Two-pronged model could help foil tough cystic fibrosis infections
10. Nanoemulsion potent against superbugs that kill cystic fibrosis patients
11. New test promises quicker, more accurate evaluation for cystic fibrosis patients
Post Your Comments:
Related Image:
Cystic Fibrosis Foundation funds Marshall research
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology: